Profile data is unavailable for this security.
About the company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
- Revenue in USD (TTM)0.00
- Net income in USD-70.96m
- Incorporated2016
- Employees73.00
- LocationXilio Therapeutics Inc828 Winter Street, Suite 300WALTHAM 02451United StatesUSA
- Phone+1 (617) 430-4680
- Fax+1 (302) 655-5049
- Websitehttps://xiliotx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Movano Inc | 852.00k | -27.91m | 37.71m | 30.00 | -- | -- | -- | 44.27 | -0.5593 | -0.5593 | 0.0168 | -0.0263 | 0.0779 | -- | 2.12 | 28,400.00 | -254.99 | -151.50 | -559.26 | -188.58 | -42.61 | -- | -3,275.47 | -- | 0.5147 | -- | -- | -- | -- | -- | 3.45 | -- | 4.24 | -- |
| Mink Therapeutics Inc | 0.00 | -20.59m | 38.19m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| Benson Hill Inc | 359.83m | -132.72m | 39.54m | 270.00 | -- | 0.5875 | -- | 0.1099 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 39.77m | 4.00 | -- | 6.59 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 39.87m | 73.00 | -- | 1.45 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 40.00m | 317.00 | -- | 0.4756 | 29.80 | 0.3327 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -25.65m | 40.77m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 40.85m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 41.06m | 32.00 | -- | 2.45 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Immuneering Corp | 0.00 | -54.18m | 41.22m | 65.00 | -- | 0.5236 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Hcw Biologics Inc | 3.93m | -27.39m | 41.23m | 45.00 | -- | 4.72 | -- | 10.50 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 41.45m | 23.00 | -- | -- | -- | 14.71 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| NKGen Biotech Inc | -100.00bn | -100.00bn | 41.56m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Clene Inc. | 620.00k | -48.81m | 42.25m | 82.00 | -- | 9.91 | -- | 68.15 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
Data as of May 30 2024. Currency figures normalised to Xilio Therapeutics Inc's reporting currency: US Dollar USD
10.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rock Springs Capital Management LPas of 31 Mar 2024 | 1.44m | 3.90% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 899.59k | 2.44% |
| Balyasny Asset Management LPas of 31 Mar 2024 | 338.54k | 0.92% |
| Columbia Investment Management Co. LLCas of 31 Dec 2023 | 249.64k | 0.68% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 249.45k | 0.68% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 221.91k | 0.60% |
| FIL Investment Advisors (UK) Ltd.as of 31 Mar 2024 | 218.71k | 0.59% |
| Geode Capital Management LLCas of 31 Mar 2024 | 84.83k | 0.23% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 71.08k | 0.19% |
| Millennium Management LLCas of 31 Mar 2024 | 70.20k | 0.19% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
